• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

AcelRx gains on Q4 earnings

March 3, 2017 By Sarah Faulkner

AcelRx gains on Q4 earningsShares in AcelRx Pharmaceuticals (NSDQ:ACRX) rose today after the pharmaceutical company met expectations on Wall Street with its 4th quarter results.

The Redwood City, Calif.-based company pared its losses to -$9.7 million, or -21¢ per share, on sales of $6.4 million for the 3 months ended Dec. 31, for bottom-line growth of 8.2% on sales growth of 276.5% compared with the same period last year.

Adjusted to exclude 1-time items, losses per share were -21¢, ahead of the -24¢ consensus on The Street.

“We have taken meaningful steps towards meeting our goal of Dsuvia approval in the U.S., and we continue to make additional commercial preparations for a potential Dsuvia launch,” CEO Howie Rosen said in prepared remarks. “A key aspect of our preparations, as we announced a few weeks ago, is having appointed Vincent J. Angotti to be chief executive officer starting March 6th. Vince has over 25 years of successful commercial experience, most recently at Xenoport, where he managed the relaunch of Horizant as COO, and as CEO led their acquisition by Arbor Pharmaceuticals. I look forward to working with Vince and the AcelRx team in my continuing role on the Board of Directors.”

AcelRx did not provide financial guidance for the full year of 2017.

ACRX shares were trading at $3.35 apiece today in afternoon trading, up 4.7%.

The company said earlier this week that the FDA accepted the company’s New Drug Application for its Dsuvia pain relief therapy. The federal watchdog set a target decision date for October 12 this year.

The company’s Dsuvia candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator to patients with moderate-to-severe acute pain resulting from trauma or injury.

Dsuvia is investigational and not approved in any country.

AcelRx’s NDA was supported by the sufentanil tablet’s clinical program, which included 4 clinical trials evaluating the sublingual painkiller as a treatment for acute pain in postoperative and emergency department patients. The data showed that patients treated with the sufentanil therapy demonstrated alleviation from pain as early as 15 minutes after they were dosed. Adverse events associated with treatment were similar to that of opioid therapy – nausea, headache, vomiting and dizziness.

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pain Management, Wall Street Beat Tagged With: AcelRx

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS